Treatment of Fungal Infections - FOI Response Register

FoI Number
2023-538
Subject
Treatment of Fungal Infections
Date Received
04/12/2023
Request and Response
  1. In the last 12 months, how many patients have been treated (for any condition) with the following drugs:
  • Amphotericin B (Ambisome)           0
  • Caspofungin (Cancidas)                 <5
  • Isavuconazole (Cresemba) 0
  • Posaconazole (Noxafil)                   <5
  • Voriconazole (VFEND)                    <5
  1. In the last 12 months, how many hospital inpatients were diagnosed with Aspergillosis (ICD10 code: B44)?

0

  1. Of the above patients diagnosed with Aspergillosis in the last 12 months, how many patients were treated with the following drugs:

All of the answers in Q1 relate to patients diagnosed with Aspergillosis

  • Amphotericin B (Ambisome)
  • Caspofungin (Cancidas)
  • Isavuconazole (Cresemba)
  • Posaconazole (Noxafil)
  • Voriconazole (VFEND)
  1. In the last 12 months, how many hospital inpatients were diagnosed with Mucormycosis (ICD10 code: B46)?

0

  1. Of the above patients diagnosed with Mucormycosis in the last 12 months, how many patients were treated with the following drugs?
  • Amphotericin B (Ambisome)
  • Isavuconazole (Cresemba)
  • Posaconazole (Noxafil

N/A

Where we have given <5 answers, this is because NHS Shetland considers that providing more detail carries a high risk of identifying individuals. As such, and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.